Adeona is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Adeona is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension (PAH), relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS).

recent press releases
rule
events

11.14.2011 – Adeona 3rd Quarter 2011 Investor Conference Call

in the newsrule

11.2.2011 – Crain's Detroit Business
 Adeona Pharmaceuticals Board Member Jeff Riley Adds Chairman’s Title

9.6.2011 – New York Times
Adjusting, More M.D.’s Add M.B.A.

8.1.2011 – MichBio LINK Newsletter
Adeona Pharmaceuticals – wellZin for the Common Cold